First patient dosed in trial of Allergan/Editas’ CRISPR blindness drugA first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, Share XFirst patient dosed in trial of Allergan/Editas’ CRISPR blindness drughttps://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/
GSK’s Walmsley gets £2.5m pay rise after strong 2019There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – Share XGSK’s Walmsley gets £2.5m pay rise after strong 2019https://pharmaphorum.com/news/gsks-walmsley-gets-2-5m-pay-rise-after-strong-sales/
AbbVie/Allergan merger cleared in EU with brazikumab sell-offAbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of Share XAbbVie/Allergan merger cleared in EU with brazikumab sell-offhttps://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerAllergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy Share XAZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerhttps://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/
FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Amgen, Allergan join Rituxan biosimilar challenge with FDA filingAmgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the Share XAmgen, Allergan join Rituxan biosimilar challenge with FDA filinghttps://pharmaphorum.com/news/amgen-allergan-join-rituxan-biosimilar-challenge-with-fda-filing/
Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
